Lamotrigine (Lamictal IR) for the treatment of bipolar disorder

Charles L. Bowden, Vivek Singh

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Introduction: Over the past decade the use of lamotrigine in bipolar disorder has increased. However, the evidence base suggests a more limited role for lamotrigine as part of an overall treatment regimen in bipolar disorder. Areas covered: We reviewed publications of randomized clinical trials of lamotrigine, emphasizing studies in bipolar disorder. The low burden of adverse effects with lamotrigine has been confirmed in these studies. Its lack of benefit in acute mania is established. Despite modest benefits for a subset of depressive episodes in bipolar disorder, it was not superior to placebo in well-designed studies. As monotherapy, in randomized, blinded trials in rapid cycling bipolar disorder it was not superior to placebo. Its role in maintenance treatment is relatively well established as one component of combination therapy, with evidence for benefits when combined with lithium or valproate. Combination regimens including lamotrigine appear to be superior to monotherapy. Monotherapy utilization of lamotrigine for maintenance treatment is not supported by these studies. Expert opinion: Lamotrigine has benefits in bipolar disorder management principally as a component of combination treatment which includes a mood stabilizer. The utility of lamotrigine in acute bipolar depression and major depressive disorder is modest.

Original languageEnglish (US)
Pages (from-to)2565-2571
Number of pages7
JournalExpert Opinion on Pharmacotherapy
Volume13
Issue number17
DOIs
StatePublished - Dec 2012

Fingerprint

Bipolar Disorder
Therapeutics
Placebos
lamotrigine
Major Depressive Disorder
Expert Testimony
Valproic Acid
Lithium
Publications
Randomized Controlled Trials

Keywords

  • Bipolar
  • Depression
  • Lamotrigine
  • Mania
  • Treatment

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Lamotrigine (Lamictal IR) for the treatment of bipolar disorder. / Bowden, Charles L.; Singh, Vivek.

In: Expert Opinion on Pharmacotherapy, Vol. 13, No. 17, 12.2012, p. 2565-2571.

Research output: Contribution to journalArticle

Bowden, Charles L. ; Singh, Vivek. / Lamotrigine (Lamictal IR) for the treatment of bipolar disorder. In: Expert Opinion on Pharmacotherapy. 2012 ; Vol. 13, No. 17. pp. 2565-2571.
@article{23340072934b4c75b805aaf160523bda,
title = "Lamotrigine (Lamictal IR) for the treatment of bipolar disorder",
abstract = "Introduction: Over the past decade the use of lamotrigine in bipolar disorder has increased. However, the evidence base suggests a more limited role for lamotrigine as part of an overall treatment regimen in bipolar disorder. Areas covered: We reviewed publications of randomized clinical trials of lamotrigine, emphasizing studies in bipolar disorder. The low burden of adverse effects with lamotrigine has been confirmed in these studies. Its lack of benefit in acute mania is established. Despite modest benefits for a subset of depressive episodes in bipolar disorder, it was not superior to placebo in well-designed studies. As monotherapy, in randomized, blinded trials in rapid cycling bipolar disorder it was not superior to placebo. Its role in maintenance treatment is relatively well established as one component of combination therapy, with evidence for benefits when combined with lithium or valproate. Combination regimens including lamotrigine appear to be superior to monotherapy. Monotherapy utilization of lamotrigine for maintenance treatment is not supported by these studies. Expert opinion: Lamotrigine has benefits in bipolar disorder management principally as a component of combination treatment which includes a mood stabilizer. The utility of lamotrigine in acute bipolar depression and major depressive disorder is modest.",
keywords = "Bipolar, Depression, Lamotrigine, Mania, Treatment",
author = "Bowden, {Charles L.} and Vivek Singh",
year = "2012",
month = "12",
doi = "10.1517/14656566.2012.741590",
language = "English (US)",
volume = "13",
pages = "2565--2571",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "17",

}

TY - JOUR

T1 - Lamotrigine (Lamictal IR) for the treatment of bipolar disorder

AU - Bowden, Charles L.

AU - Singh, Vivek

PY - 2012/12

Y1 - 2012/12

N2 - Introduction: Over the past decade the use of lamotrigine in bipolar disorder has increased. However, the evidence base suggests a more limited role for lamotrigine as part of an overall treatment regimen in bipolar disorder. Areas covered: We reviewed publications of randomized clinical trials of lamotrigine, emphasizing studies in bipolar disorder. The low burden of adverse effects with lamotrigine has been confirmed in these studies. Its lack of benefit in acute mania is established. Despite modest benefits for a subset of depressive episodes in bipolar disorder, it was not superior to placebo in well-designed studies. As monotherapy, in randomized, blinded trials in rapid cycling bipolar disorder it was not superior to placebo. Its role in maintenance treatment is relatively well established as one component of combination therapy, with evidence for benefits when combined with lithium or valproate. Combination regimens including lamotrigine appear to be superior to monotherapy. Monotherapy utilization of lamotrigine for maintenance treatment is not supported by these studies. Expert opinion: Lamotrigine has benefits in bipolar disorder management principally as a component of combination treatment which includes a mood stabilizer. The utility of lamotrigine in acute bipolar depression and major depressive disorder is modest.

AB - Introduction: Over the past decade the use of lamotrigine in bipolar disorder has increased. However, the evidence base suggests a more limited role for lamotrigine as part of an overall treatment regimen in bipolar disorder. Areas covered: We reviewed publications of randomized clinical trials of lamotrigine, emphasizing studies in bipolar disorder. The low burden of adverse effects with lamotrigine has been confirmed in these studies. Its lack of benefit in acute mania is established. Despite modest benefits for a subset of depressive episodes in bipolar disorder, it was not superior to placebo in well-designed studies. As monotherapy, in randomized, blinded trials in rapid cycling bipolar disorder it was not superior to placebo. Its role in maintenance treatment is relatively well established as one component of combination therapy, with evidence for benefits when combined with lithium or valproate. Combination regimens including lamotrigine appear to be superior to monotherapy. Monotherapy utilization of lamotrigine for maintenance treatment is not supported by these studies. Expert opinion: Lamotrigine has benefits in bipolar disorder management principally as a component of combination treatment which includes a mood stabilizer. The utility of lamotrigine in acute bipolar depression and major depressive disorder is modest.

KW - Bipolar

KW - Depression

KW - Lamotrigine

KW - Mania

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84869830298&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869830298&partnerID=8YFLogxK

U2 - 10.1517/14656566.2012.741590

DO - 10.1517/14656566.2012.741590

M3 - Article

C2 - 23140205

AN - SCOPUS:84869830298

VL - 13

SP - 2565

EP - 2571

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 17

ER -